PMID- 35548751
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 8
IP  - 54
DP  - 2018 Aug 30
TI  - Therapeutic efficacy of polydatin for nonalcoholic fatty liver disease via 
      regulating inflammatory response in obese mice.
PG  - 31194-31200
LID - 10.1039/c8ra05915b [doi]
AB  - Polydatin (PD), a natural precursor of resveratrol, has been used to treat 
      several diseases, such as cardiovascular diseases, hepatic diseases and various 
      cancers. In this study, we aimed to investigate the protective effects and 
      underlying mechanisms of PD on non-alcoholic fatty liver disease (NAFLD) using a 
      high fat induced obese mice model. The studied subjects were randomly divided 
      into a lean group, a high fat diet (HFD) group, and a high fat diet with PD (HFD 
      + PD) group. The results showed that PD reduced the body weights in HFD mice. PD 
      also downregulated the serum levels of triglyceride (TG), low density lipoprotein 
      (LDL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and 
      upregulated high density lipoprotein (HDL). Moreover, PD significantly alleviated 
      hepatocyte steatosis and reduced Gr-1(+) cells in the liver tissues of HFD mice. 
      The mRNA levels of pro-inflammatory factors, such as monocyte chemoattractant 
      protein-1 (MCP-1), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), 
      S100A8 and S100A9 were significantly decreased in the liver tissues of HFD mice 
      with PD treatment, and the downregulation of MCP-1 and S100A9 protein expressions 
      was also observed. In conclusion, PD had beneficial roles in suppressing lipid 
      accumulation in hepatocytes and anti-inflammatory responses in the liver tissue 
      of obese associated NAFLD.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Mo, Juan-Fen
AU  - Mo JF
AUID- ORCID: 0000-0002-5858-1659
AD  - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University 1518 
      Huancheng North Road Jiaxing Zhejiang 314000 China baoyi@jxey.com 
      +86-573-82082936 +86-573-82073185.
FAU - Wu, Jia-Yuan
AU  - Wu JY
AD  - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University 1518 
      Huancheng North Road Jiaxing Zhejiang 314000 China baoyi@jxey.com 
      +86-573-82082936 +86-573-82073185.
FAU - Zheng, Li
AU  - Zheng L
AD  - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University 1518 
      Huancheng North Road Jiaxing Zhejiang 314000 China baoyi@jxey.com 
      +86-573-82082936 +86-573-82073185.
FAU - Yu, Ya-Wei
AU  - Yu YW
AD  - Department of Pathology, The Second Affiliated Hospital of Jiaxing University 
      Jiaxing Zhejiang 314000 China.
FAU - Zhang, Tian-Xin
AU  - Zhang TX
AD  - Clinical Laboratory, The Second Affiliated Hospital of Jiaxing University Jiaxing 
      Zhejiang 314000 China.
FAU - Guo, Li
AU  - Guo L
AD  - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University 1518 
      Huancheng North Road Jiaxing Zhejiang 314000 China baoyi@jxey.com 
      +86-573-82082936 +86-573-82073185.
FAU - Bao, Yi
AU  - Bao Y
AD  - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University 1518 
      Huancheng North Road Jiaxing Zhejiang 314000 China baoyi@jxey.com 
      +86-573-82082936 +86-573-82073185.
LA  - eng
PT  - Journal Article
DEP - 20180905
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9085635
COIS- There are no conflicts of interest to declare.
EDAT- 2018/09/05 00:00
MHDA- 2018/09/05 00:01
PMCR- 2018/09/05
CRDT- 2022/05/13 11:29
PHST- 2018/07/11 00:00 [received]
PHST- 2018/08/19 00:00 [accepted]
PHST- 2022/05/13 11:29 [entrez]
PHST- 2018/09/05 00:00 [pubmed]
PHST- 2018/09/05 00:01 [medline]
PHST- 2018/09/05 00:00 [pmc-release]
AID - c8ra05915b [pii]
AID - 10.1039/c8ra05915b [doi]
PST - epublish
SO  - RSC Adv. 2018 Sep 5;8(54):31194-31200. doi: 10.1039/c8ra05915b. eCollection 2018 
      Aug 30.